Astex Pharmaceuticals, Inc. engages in the discovery and development of small molecule therapeutics with a focus on oncology and hematology. It develops small molecule therapeutics using its fragment-based drug discovery platform, Pyramid. The company offers Dacogen (decitabine) for injection, a DNA hypomethylating agent for the treatment of myelodysplastic syndromes (MDS). Its product pipeline includes Dacogen-Hypomethylator, a phase III clinical trial product for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML); AT13387, a small molecule inhibitor of Hsp90, which is completing a Phase I study in patients with advanced refractory tumors and in Phase II study for the treatment of refractory GIST patients; SGI-110, a small molecule, DNA-hypomethyating agent in Phase I clinical trial for MDS and AML; and Amuvatinib/MP-470 (SCLC), a tyrosine kinase inhibitor, which is in Phase II clinical trial for various cancer targets, including mutant c-Kit. The company’s products under development also comprise AT7519 that is in a Phase II study in combination with bortezomib for multiple myeloma; AT13148, an orally active small molecule inhibitor of PKB/Akt and p70S6 kinase to commence Phase I clinical trial for the treatment of solid tumors; and AT9283, which is in two Phase I, open-label, dose-escalation trials for advanced solid tumors and in a Phase I/II open-label, dose-escalation trial for patients with acute leukemia. In addition, it develops LEE011, a Phase I human clinical trial CDK4 inhibitor; AZD5363, an orally active, selective protein kinase B inhibitor in Phase I clinical trial; and FGFr inhibitor for the treatment of cancer, as well as AZD3839, a Phase I study beta-secretase inhibitor for treating Alzheimer's disease. The company was formerly known as SuperGen, Inc. and changed its name to Astex Pharmaceuticals, Inc. in September 2011. The company was founded in 1991 and is headquartered in Dublin, California.